EUCTR2009-012185-32-IT进行中（未招募）不适用
Open label, multicentric phase IIIb study to evaluate the effect of tocilizumab in combination with DMARDs in the inhibition of progression of synovitis, bone marrow edema, and erosions evaluated by dedicated magnetic resonance imaging (MRI) in the hand of patients with rheumatoid arthritis (RA) - ND
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- ROCHE
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Men and women ≥ 18 years of age with a diagnosis of RA of ≥ 6 months duration, who are currently experiencing moderate to severe active RA (DAS28 > 3.2) and an inadequate clinical response to a stable dose of non-biologic DMARD therapy - Inclusion criteria 1.Male or non-pregnant, non-nursing female 2.Age ≥ 18 years 3.Patients with diagnosis of RA of ≥ 6 months duration 4.Patients currently experiencing moderate to severe active RA (DAS28 > 3.2) 5.Patients with: SJ ≥ 6; TJ ≥ 8 6.Patients receiving treatment on an outpatient basis 7.Patients with inadequate clinical response to a stable dose of non-biologic DMARD for at least 2 months 8.If patients are receiving an oral corticosteroid, the dose must have been stable for at least 25 out of 28 days prior to treatment (baseline) 9.Subjects able and willing to give written informed consent and comply with the requirements of the study protocol.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Disease-specific criteria: 1.Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months following randomization 2.Rheumatic autoimmune disease other than RA, including systemic lupus erythematosus (SLE), mixed connective tissue disease (MCTD), systemic sclerosis, polymyositis, or significant systemic involvement secondary to RA (e.g. vasculitis, pulmonary fibrosis or Felty?s syndrome). Patient with interstitial pulmonary fibrosis and still able to tolerate MTX therapy can be included in the study. Patients with secondary Sj?gren?s Syndrome associated with RA can be included in the study 3.Functional class IV as defined by the ACR Classification of Functional Status in RA (largely or wholly incapacitated with patient bedridden or confined to wheel chair, permitting little or no self-care) 4.Prior history of or current inflammatory joint disease other than RA (e.g. gout, reactive arthritis, psoriatic arthritis, seronegative spondyloarthropathy, Lyme disease) Drug-specific criteria: 5.Treatment with any investigational agent within 4 weeks (or 5 half-lives of investigational agent, whichever is longer) before screening 6.Previous inadequate response to treatment with biologic DMARDs Previous biologic treatment allowed if assumed for no more than 1 month and stopped for tolerability reasons at least 6 months before the enrollment in the study. 7.Intraarticular or parenteral corticosteroids within 6 weeks prior to baseline 8.Immunization with a live/attenuated vaccine within 4 weeks prior to baseline 9.Previous treatment with tocilizumab (an exception to this criterion may be granted for single-dose exposure upon application to the sponsor on a case by case basis) 10.Any previous treatment with alkylating agents, such as cyclophosphamide or chlorambucil, or with total lymphoid irradiation Laboratory-specific criteria (at screening): 11.Serum creatinine > 142 μmol/L (1.6 mg/dL) in female patients and > 168 μmol/L (1.9 mg/dL) in male patients 12.ALT (SGPT) or AST (SGOT) > 1.5 ULN (If initial sample yields ALT [SGPT] or AST [SGOT] > 1.5 ULN, a second sample may be taken and tested during the screening period) 13.Platelet count < 100 x 109/L (100,000/mm3) 14.Hemoglobin < 80 g/L (8 g/dL) 15.WBC count <1.0 x 109/L (1000/mm3), ANC < 0.5 x 109/L (500/mm3) 16.ALC < 0.5 x 109/L (500/mm3) 17.Positive hepatitis B surface antigen (HBsAg) or hepatitis C antibody 18.Total bilirubin > ULN (If initial sample yields bilirubin > ULN, a second sample may be taken and tested during the screening period) 19.Triglycerides > 10 mmol/L (> 900 mg/dL) at screening (non-fasted) General medical: 20.Pregnant women or nursing (breastfeeding) mothers 21.Females of child-bearing potential who are not using a reliable method of contraception 22.History of severe allergic or anaphylactic reactions to human, humanized, or murine monoclonal antibodies 23.History of severe or anaphylactic reactions to gadolinium. 24.Chest X-ray evidence of any clinically significant abnormality. 25.Evidence of serious uncontrolled concomitant cardiovascular, nervous system, pulmonary (including obstructive pulmonary disease), renal, hepatic, endocrine (including uncontrolled diabetes mellitus) or GI disease. Et al.
研究者
相似试验
进行中（未招募）
1 期
ot applicableRheumatoid ArthritisEUCTR2013-000359-42-GRROCHE HELLAS S.A.
已完成
3 期
A Clinical Trial to study the effects of Rituximab in patients with Non Hodgkin's Lymphoma.CTRI/2010/091/001195Zenotech Laboratories limited,8-2-120 /112 /88-89, Park View Estate, 4th Floor, Road No. 2, Banjara Hills, Hyderabad. Tel: +91 40 2354 0994Fax: +91 40 2355 546550
招募中
1 期
A 24-month study evaluating physical activity and joint health in patients 12 years and older, with severe haemophilia A treated once weekly with efanesoctocog alfa.Haemophilia AMedDRA version: 20.0Level: LLTClassification code: 10018937Term: Haemophilia A Class: 10010331CTIS2022-500275-31-00Swedish Orphan Biovitrum AB (publ)94
进行中（未招募）
不适用
Immunogenicity and reactogenicity study of GlaxoSmithKline Biologicals’ Infanrix™/Hib vaccine administered as a booster dose to 18-24 months old children.EUCTR2015-001507-31-Outside-EU/EEAGlaxoSmithKline Biologicals - GSK China Vaccines630
进行中（未招募）
1 期
An open-label, multicenter, phase IIIb study assessing the long-term efficacy and safety of AOP2014 and standard first line treatment (BAT) in patients with Polycythemia Vera who previously participated in the PROUD-PV StudyPolycythemia VeraEUCTR2014-001357-17-BGAOP Orphan Pharmaceuticals AG200